Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414244 · ClinicalTrials.gov registry record · Phase 2
Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
A Phase 2 study of Diarrhea-Predominant Irritable Bowel Syndrome, sponsored by Tulane University.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT01414244 is a Phase 2 study of Diarrhea-Predominant Irritable Bowel Syndrome that has completed, run by Tulane University. The registered enrollment target is 106 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01414244, a Phase 2 study of Diarrhea-Predominant Irritable Bowel Syndrome, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an enteric infection.
Conditions Studied
Interventions
- DRUG Glutamine
Study Locations (1)
Louisiana
- Tulane University School of Medicine - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01414244
The ClinicalTrials.gov registry entry for NCT01414244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diarrhea-Predominant Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Glutamine is the first listed.
NCT01414244 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT01414244 about?
NCT01414244 is a clinical study titled "Glutamine for the Treatment of Patients With Irritable Bowel Syndrome". New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who ...
What is the current status of trial NCT01414244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2010-11. Estimated completion is 2015-12-30.
What conditions does trial NCT01414244 study?
This clinical trial studies the following conditions: Diarrhea-Predominant Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01414244?
The interventions under investigation include: Glutamine (DRUG).
Who is sponsoring clinical trial NCT01414244?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01414244 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea-Predominant Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.